The pathomimetic oAß25-35 model of Alzheimer's disease: Potential for screening of new therapeutic agents.
Pharmacol Ther
; 245: 108398, 2023 05.
Article
em En
| MEDLINE
| ID: mdl-37001735
ABSTRACT
Alzheimer's disease (AD) is the most common form of dementia in the elderly, currently affecting more than 40 million people worldwide. The two main histopathological hallmarks of AD were identified in the 1980s senile plaques (composed of aggregated amyloid-ß (Aß) peptides) and neurofibrillary tangles (composed of hyperphosphorylated tau protein). In the human brain, both Aß and tau show aggregation into soluble and insoluble oligomers. Soluble oligomers of Aß include their most predominant forms - Aß1-40 and Aß1-42 - as well as shorter peptides such as Aß25-35 or Aß25-35/40. Most animal models of AD have been developed using transgenesis, based on identified human mutations. However, these familial forms of AD represent less than 1% of AD cases. In this context, the idea emerged in the 1990s to directly inject the Aß25-35 fragment into the rodent brain to develop an acute model of AD that could mimic the disease's sporadic forms (99% of all cases). This review aims to (1) summarize the biological activity of Aß25-35, focusing on its impact on the main structural and functional alterations observed in AD (cognitive deficits, APP misprocessing, tau system dysfunction, neuroinflammation, oxidative stress, cholinergic and glutamatergic alterations, HPA axis dysregulation, synaptic deficits and cell death); and (2) confirm the interest of this pathomimetic model in AD research, as it has helped identify and characterize many molecules (marketed, in clinical development, and in preclinical testing), and to the development of alternative approaches for AD prevention and therapy. Today, the Aß25-35 model appears as a first-intent choice model to rapidly screen the symptomatic or neuroprotective potencies of new compounds, chemical series, or innovative therapeutic strategies.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doença de Alzheimer
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article